MCID: PTH002
MIFTS: 48

Pathological Gambling

Categories: Mental diseases

Aliases & Classifications for Pathological Gambling

MalaCards integrated aliases for Pathological Gambling:

Name: Pathological Gambling 12 14
Compulsive Gambling 12 41
Gambling, Pathological 69
Gambling 42

Classifications:



External Ids:

Disease Ontology 12 DOID:12399
ICD10 33 F63.0
ICD9CM 35 312.31
MeSH 42 D005715
NCIt 47 C94335
UMLS 69 C0030662

Summaries for Pathological Gambling

MedlinePlus : 41 many people enjoy gambling, whether it's betting on a horse or playing poker on the internet. most people who gamble don't have a problem, but some lose control of their gambling. signs of problem gambling include always thinking about gambling lying about gambling spending work or family time gambling feeling bad after you gamble, but not quitting gambling with money you need for other things if you have concerns about your gambling, ask for help. your health care provider can work with you to find the treatment that's best for you. nih: national institutes of health

MalaCards based summary : Pathological Gambling, also known as compulsive gambling, is related to antisocial personality disorder and personality disorder. An important gene associated with Pathological Gambling is DRD4 (Dopamine Receptor D4), and among its related pathways/superpathways are Beta-Adrenergic Signaling and Signaling in Gap Junctions. The drugs Topiramate and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and cortex, and related phenotypes are shRNA abundance <= 50% and behavior/neurological

Disease Ontology : 12 An impulse control disorder that involves the uncontrollable impulse to gamble, irrespective of the interference the behaviour has on the individual's life.

Related Diseases for Pathological Gambling

Diseases related to Pathological Gambling via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 109)
id Related Disease Score Top Affiliating Genes
1 antisocial personality disorder 30.0 DRD2 DRD3 DRD4
2 personality disorder 27.4 DRD2 DRD3 DRD4 HTR2A MAOA SLC6A3
3 schizophrenia 25.2 DRD1 DRD2 DRD3 DRD4 HTR2A MAOA
4 congenital chloride diarrhea 11.4
5 dissociative disorder 10.4 DRD3 SLC6A4
6 hypertrophy of breast 10.3 DRD4 SLC6A3
7 placenta disease 10.3 DRD2 DRD3 DRD4
8 anosognosia 10.3 DRD2 SLC6A4
9 anodontia 10.2 SLC6A3 SLC6A4
10 allergic hypersensitivity disease 10.2 DRD2 HTR2A
11 vascular cancer 10.2 DRD2 HTR2A
12 eosinophilia-myalgia syndrome 10.2 DRD2 DRD4 SLC6A3
13 asperger syndrome 10.2 DRD2 DRD3 SLC6A3
14 conjunctival degeneration 10.2 HTR2A SLC6A4
15 simpson-golabi-behmel syndrome 10.1 DRD2 SLC6A3
16 thyrotropin-releasing hormone deficiency 10.1 DRD3 SLC6A3
17 ganglioneuroma 10.1 DRD2 DRD3 SLC6A3
18 c8 deficiency, type ii 10.1 DRD1 DRD2 DRD4
19 obsessive-compulsive disorder 10.1
20 teebi kaurah syndrome 10.1 DRD2 DRD3 HTR2A
21 osteogenesis imperfecta, type ix 10.1 DRD2 DRD4 SLC6A3
22 suppurative periapical periodontitis 10.1 DRD2 DRD3 SLC6A4
23 uterus intravascular leiomyomatosis 10.0 MAOA SLC6A4
24 hallucinogen dependence 10.0 DRD2 DRD3 SLC6A4
25 intracranial cavernous angioma 10.0 DRD2 SLC6A3 SLC6A4
26 renpenning syndrome 10.0 MAOA SLC6A4
27 bladder hepatoid adenocarcinoma 10.0 DRD2 SLC6A3 SLC6A4
28 alcohol dependence 9.9
29 pervasive developmental disorder 9.9 DRD4 SLC6A3 SLC6A4
30 perinatal necrotizing enterocolitis 9.9 DRD2 SLC6A3 SLC6A4
31 angiokeratoma of mibelli 9.9 MAOA SLC6A4
32 cocaine dependence 9.9
33 dementia 9.9
34 tubular variant testicular seminoma 9.9 MAOB SLC6A3
35 hyperthyroxinemia 9.9 DRD2 HTR2A SLC6A4
36 pompholyx 9.9 DRD2 HTR2A SLC6A4
37 laryngeal adductor paralysis 9.9 DRD4 HTR2A SLC6A4
38 pelvic inflammatory disease 9.9 DRD2 SLC6A4
39 drug addiction 9.8
40 alcohol abuse 9.8
41 substance abuse 9.8
42 mood disorder 9.8
43 restless legs syndrome 9.8
44 alexithymia 9.8
45 eating disorder 9.8
46 impulse control disorder 9.8
47 substance dependence 9.8
48 ornithosis 9.8 DRD2 MAOA SLC6A4
49 primary angle-closure glaucoma 9.8 DRD1 HTR2A SLC6A4
50 alcoholic liver cirrhosis 9.8 DRD2 DRD3 DRD4 SLC6A4

Graphical network of the top 20 diseases related to Pathological Gambling:



Diseases related to Pathological Gambling

Symptoms & Phenotypes for Pathological Gambling

GenomeRNAi Phenotypes related to Pathological Gambling according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 shRNA abundance <= 50% GR00343-S 9.17 DRD1 DRD2 DRD3 DRD4 HTR2A MAOA

MGI Mouse Phenotypes related to Pathological Gambling:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.91 DRD1 DRD2 DRD3 DRD4 HTR2A MAOA
2 homeostasis/metabolism MP:0005376 9.76 DRD1 DRD2 DRD3 DRD4 MAOA MAOB
3 muscle MP:0005369 9.35 DRD1 DRD2 HTR2A SLC6A3 SLC6A4
4 nervous system MP:0003631 9.23 MAOB SLC6A3 SLC6A4 DRD1 DRD2 DRD3

Drugs & Therapeutics for Pathological Gambling

Drugs for Pathological Gambling (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 80)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Topiramate Approved Phase 4,Phase 2 97240-79-4 5284627
2
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
3
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
4
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 16590-41-3 5360515
5
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
6
Ethanol Approved Phase 4,Phase 2 64-17-5 702
7
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
8
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 5095 497540
9 Anticonvulsants Phase 4,Phase 2
10 Anti-Obesity Agents Phase 4,Phase 2
11 Neuroprotective Agents Phase 4,Phase 2
12 Protective Agents Phase 4,Phase 2,Phase 1
13 Central Nervous System Stimulants Phase 4,Phase 2
14 Dopamine Agents Phase 4,Phase 2
15 Dopamine Uptake Inhibitors Phase 4,Phase 2
16 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
17 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2
18 Narcotic Antagonists Phase 4,Phase 2,Phase 3
19 Narcotics Phase 4,Phase 2,Phase 3
20 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3
21 Dopamine agonists Phase 4
22 Autonomic Agents Phase 4,Phase 3,Phase 2
23
Olanzapine Approved, Investigational Phase 3 132539-06-1 4585
24
nalmefene Phase 2, Phase 3 55096-26-9 5284594
25 Antiemetics Phase 3,Phase 2
26 Antipsychotic Agents Phase 3,Phase 2
27 Central Nervous System Depressants Phase 3,Phase 2
28 Gastrointestinal Agents Phase 3,Phase 2
29 Psychotropic Drugs Phase 3,Phase 2
30
Serotonin Phase 3,Phase 2 50-67-9 5202
31 Serotonin Agents Phase 3,Phase 2
32 Serotonin Uptake Inhibitors Phase 3,Phase 2
33 Tranquilizing Agents Phase 3,Phase 2
34
Coal tar Approved Phase 2 8007-45-2
35
Memantine Approved, Investigational Phase 2 19982-08-2 4054
36
Amphetamine Approved, Illicit Phase 2 300-62-9 5826 3007
37
Dextroamphetamine Approved, Illicit Phase 2 51-64-9 5826
38
Fluphenazine Approved Phase 2 69-23-8 3372
39
Haloperidol Approved Phase 2 52-86-8 3559
40
Naloxone Approved, Vet_approved Phase 2 465-65-6 5284596
41
Acetylcysteine Approved, Investigational Phase 2,Phase 1 616-91-1 12035
42
Nicotine Approved Phase 2 54-11-5 942 89594
43
Sertraline Approved Phase 2 79617-96-2 68617
44 Ecopipam Investigational Phase 2 112108-01-7
45 Antiparkinson Agents Phase 2
46 Excitatory Amino Acid Antagonists Phase 2
47 Excitatory Amino Acids Phase 2
48 Catechol O-Methyltransferase Inhibitors Phase 2
49 Dopamine Antagonists Phase 2
50 Adrenergic Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 67)

id Name Status NCT ID Phase Drugs
1 Topiramate in the Treatment of Pathological Gambling Unknown status NCT00245583 Phase 4 topiramate (Topomax)
2 Methylphenidate in ADHD With Trichotillomania Unknown status NCT00552266 Phase 4 Methylphenidate
3 Treatment of Pathological Gambling With Naltrexone Pharmacotherapy and Brief Intervention Completed NCT01528007 Phase 4 Naltrexone pharmacotherapy;Placebo
4 Acamprosate in the Treatment of Pathological Gambling Completed NCT00571103 Phase 4 acamprosate
5 Naltrexone for Impulse Control Disorders in Parkinson's Disease Completed NCT01052831 Phase 4 Naltrexone;Placebo
6 Behavioural Addictions Occurring During a Dopaminergic Treatment Prescribe Under Parkinson's Disease: Study of the Psychopathological, Neurological, Pharmacokinetic and Genetic Profiles Recruiting NCT01733199 Phase 4
7 Nalmefene Gambling Study: Study of Nalmefene HCl in the Treatment of Pathological Gambling Completed NCT00132119 Phase 2, Phase 3 nalmefene HCl
8 Safety and Efficacy Trial of Olanzapine in Outpatients With Pathological Gambling Completed NCT00438776 Phase 3 olanzapine;sugar pill
9 Drug Treatment for Pathologic Gambling Disorder Completed NCT00053677 Phase 3 Naltrexone;Placebo
10 Minimal and Brief Treatments for Pathological Gamblers Completed NCT00203645 Phase 3
11 Community Reinforcement Approach and Family Training (CRAFT) for Problem Gambling Unknown status NCT01340274 Phase 2
12 Web-based vs In-person Personalized Feedback Intervention for Comorbid Substance Use and Disordered Gambling Unknown status NCT01529047 Phase 2
13 Investigation of Naltrexone for Pathological Gambling Completed NCT01057862 Phase 2 Naltrexone
14 Memantine Treatment Study of Pathological Gambling Completed NCT00585169 Phase 2 Memantine Hydrochloride
15 Tolcapone Treatment of Pathological Gambling Completed NCT00927563 Phase 2 Tolcapone
16 Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble Completed NCT01215357 Phase 2 Ecopipam
17 Cognitive Behavioral Therapy for Pathological Gambling Completed NCT00337753 Phase 2
18 Cognitive Behavioral Treatments for Pathological Gambling Completed NCT00618462 Phase 2
19 A Pilot SMART Design for Pathological Gamblers Completed NCT00685724 Phase 2
20 D1 and D2 Dopamine Receptors in Gambling and Amphetamine Reinforcement Completed NCT02203786 Phase 2 Haloperidol;Fluphenazine;Dexedrine;Placebo
21 Topiramate Trial for Pathological Gamblers Completed NCT01843699 Phase 2 Topiramate flexible dosage;Placebo matching tablets
22 Treatment of Gambling Disorder With Fast Acting Opiate Antagonist, Naloxone Nasal Spray Completed NCT03223896 Phase 2 Naloxone hydrochloride 20mg/ml
23 Indicated Prevention With At-Risk Gamblers Completed NCT00078273 Phase 2
24 N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers Completed NCT00967005 Phase 2 N Acetyl Cysteine
25 Milk Thistle in Pathological Gambling Recruiting NCT02337634 Phase 2 Placebo;Milk Thistle
26 SBIRT Intervention for Gambling Behaviors Not yet recruiting NCT03287583 Phase 2
27 Evaluation of Nalmefene in Impulse Control Disorders in Parkinson's Disease: A Prospective Open Label Study Not yet recruiting NCT02934919 Phase 2 Nalmefene
28 Effectiveness of Sertraline in Treating Pathological Gamblers With a Diagnosis of Alcohol Dependence - 1 Terminated NCT00249431 Phase 2 Sertraline
29 Deep Low-Frequency Repetitive Transcranial Magnetic Stimulation for Cessation of Pathological Gambling Unknown status NCT01154712 Phase 1
30 An Open-Label Study of N-Acetyl Cysteine in Pathological Gambling Completed NCT00273702 Phase 1 N-Acetyl Cysteine
31 Cognitive Behavioral Therapy for Treatment of Pathological Gambling Completed NCT00158314 Phase 1
32 Cognitive-Behavioral Treatment of Gambling Completed NCT00118391 Phase 1
33 Cognitive Motivational Behavior Therapy for Gamblers Completed NCT00069420 Phase 1
34 Effectiveness of Therapy Treatment Unknown status NCT01596478
35 Descriptive Study of a French Sample of “at Risk” and Pathological Gamblers Followed in a French Structure Specialised in Addictive Disorders. Unknown status NCT00360321
36 A Prospective Clinical Study of a Cohort of Pathological or "at Risk" Gamblers Seeking Treatment Unknown status NCT01248767
37 Transversal Multiaxial Evaluation and 5-year Follow-up of a Cohort of French Gamblers (JEU) Unknown status NCT01207674
38 Effects of Internet-based Treatment of Pathological Gambling Completed NCT01381250
39 Bupropion in the Treatment of Pathological Gambling Completed NCT00055393 Bupropion;Placebo
40 Impulsivity in Pathological Gambling Completed NCT00580567
41 Naltrexone in the Treatment of Concurrent Alcohol Dependence and Pathological Gambling Completed NCT00326807 Naltrexone
42 Cognitive-Motivational Behavior Therapy for Pathological Gamblers Completed NCT01135264
43 Testing Resources: Manual and Webinar Guided Treatment vs. Manual Guided Treatment Completed NCT01743092
44 Dopamine Responsivity in Gamblers Completed NCT02772978 Tolcapone;Placebo
45 Effect of rTMS in Pathological Gamblers Completed NCT02552524
46 A Personalized Feedback Intervention for Problem Gamblers Completed NCT00578357
47 A Transversal Study for the French Validation of Two Assessment Tools of Gambling Related Cognitions. Completed NCT01219426
48 Development and Validation of a Mindfulness Intervention for Problem Gambling: An Exploratory Study Completed NCT00495261
49 Susceptibility to Pathological Gambling Recruiting NCT01528982
50 The Efficacy of Therapy Focused on Desire-satisfaction for Disordered Gamblers Recruiting NCT02491996

Search NIH Clinical Center for Pathological Gambling

Cochrane evidence based reviews: gambling

Genetic Tests for Pathological Gambling

Anatomical Context for Pathological Gambling

MalaCards organs/tissues related to Pathological Gambling:

39
Testes, Brain, Cortex, Prefrontal Cortex, Subthalamic Nucleus, Pituitary, Skin

Publications for Pathological Gambling

Articles related to Pathological Gambling:

(show top 50) (show all 579)
id Title Authors Year
1
Partial dopamine agonist-induced pathological gambling and impulse-control deficit on low-dose aripiprazole. ( 28696131 )
2017
2
Comorbid pathological gambling, mental health, and substance use disorders: Health-care services provision by clinician specialty. ( 28856904 )
2017
3
Identifying Environmental and Social Factors Predisposing to Pathological Gambling Combining Standard Logistic Regression and Logic Learning Machine. ( 28255941 )
2017
4
Pathological Gambling and Motor Impulsivity: A Systematic Review with Meta-Analysis. ( 28255940 )
2017
5
A prospective follow-up study of younger and older subjects with pathological gambling. ( 28645075 )
2017
6
Prevalence of pathological gambling in patients with alcohol dependence syndrome attending a tertiary care center in South India. ( 28483101 )
2017
7
Post-traumatic stress symptoms in pathological gambling: Potential evidence of anti-reward processes. ( 28274137 )
2017
8
Health Outcomes in Individuals with Problem and Pathological Gambling: An Analysis of the 2014 North Carolina Behavioral Risk Factor Survey System (BRFSS). ( 28864873 )
2017
9
Pathological gambling. ( 28381496 )
2017
10
Relationship between pathological gambling, alexithymia, and gambling type. ( 28211964 )
2017
11
Personality disorders and pathological gambling. ( 27798487 )
2017
12
Predictability in Pathological Gambling? Applying the Duplication of Purchase Law to the Understanding of Cross-Purchases Between Regular and Pathological Gamblers. ( 27328818 )
2016
13
Intergenerational Childhood Maltreatment in Persons with DSM-IV Pathological Gambling and Their First-Degree Relatives. ( 26749583 )
2016
14
Frontal cortex gray matter volume alterations in pathological gambling occur independently from substance use disorder. ( 26771165 )
2016
15
The association between pathological gambling and suicidality in treatment-seeking pathological gamblers in South Africa. ( 26855985 )
2016
16
Pathological gambling: a behavioral addiction. ( 27717269 )
2016
17
Dopamine and Opioid Neurotransmission in Behavioral Addictions: A Comparative PET Study in Pathological Gambling and Binge Eating. ( 27882998 )
2016
18
Pathological Gambling in Parkinson's disease patients: Dopaminergic medication or personality traits fault? ( 27288799 )
2016
19
Impulsivity, implicit attitudes and explicit cognitions, and alcohol dependence as predictors of pathological gambling. ( 27614152 )
2016
20
Pathological gambling in Parkinson's disease: what are the risk factors and what is the role of impulsivity? ( 27623191 )
2016
21
Pathological Gambling Associated With Aripiprazole or Dopamine Replacement Therapy: Do Patients Share the Same Features? A Review. ( 26658263 )
2016
22
Pathological gambling: a review of the neurobiological evidence relevant for its classification as an addictive disorder. ( 26935000 )
2016
23
Cognitive distortions and ADHD in pathological gambling: A national longitudinal case-control cohort study. ( 27774813 )
2016
24
Pathological Gambling and Associated Drug and Alcohol Abuse, Emotion Regulation, and Anxious-Depressive Symptomatology. ( 27348555 )
2016
25
Development and validation of the Gambling Follow-up Scale, Self-Report version: an outcome measure in the treatment of pathological gambling. ( 27828667 )
2016
26
A Randomised, Double-Blind, Placebo-Controlled Trial of As-Needed Naltrexone in the Treatment of Pathological Gambling. ( 26339899 )
2016
27
Effects of High Frequency Repeated Transcranial Magnetic Stimulation and Continuous Theta Burst Stimulation on Gambling Reinforcement, Delay Discounting, and Stroop Interference in Men with Pathological Gambling. ( 27350401 )
2016
28
Genome-wide association study of pathological gambling. ( 27315593 )
2016
29
A Preliminary Study of DBH (Encoding Dopamine Beta-Hydroxylase) Genetic Variation and Neural Correlates of Emotional and Motivational Processing in Individuals With and Without Pathological Gambling. ( 27194378 )
2016
30
Assessing the effects of cocaine dependence and pathological gambling using group-wise sparse representation of natural stimulus FMRI data. ( 27704410 )
2016
31
Increased corticolimbic connectivity in cocaine dependence versus pathological gambling is associated with drug severity and emotion-related impulsivity. ( 25818325 )
2015
32
Towards a Validation of the Three Pathways Model of Pathological Gambling. ( 25980378 )
2015
33
Impaired Decision-Making, Higher Impulsivity, and Drug Severity in Substance Dependence and Pathological Gambling. ( 25918968 )
2015
34
Neurobiological correlates of internet gaming disorder: Similarities to pathological gambling. ( 26621112 )
2015
35
Thresholds of probable problematic gambling involvement for the German population: Results of the Pathological Gambling and Epidemiology (PAGE) Study. ( 26415065 )
2015
36
Age at onset of DSM-IV pathological gambling in a non-treatment sample: Early- versus later-onset. ( 25956751 )
2015
37
Early-onset frontotemporal dementia presenting with pathological gambling. ( 25682087 )
2015
38
Sexual abuse, residential schooling and probable pathological gambling among Indigenous Peoples. ( 25816756 )
2015
39
Discussion of masochism and pathological gambling: a review of masochism. ( 25734873 )
2015
40
Pathological gambling associated with CADASIL: an unusual manifestation. ( 26142163 )
2015
41
Predicting treatment failure in pathological gambling: the role of personality traits. ( 25555154 )
2015
42
Masochism and pathological gambling. ( 25734872 )
2015
43
Increased impulsivity in pathological gambling: Considering nicotine dependence. ( 25819174 )
2015
44
Towards a comprehensive developmental model of pathological gambling. ( 25879250 )
2015
45
Pathological Gambling Due to Aripiprazole: Two Cases. ( 27617507 )
2015
46
Working memory, executive function and impulsivity in Internet-addictive disorders: a comparison with pathological gambling. ( 26400106 )
2015
47
Correction: Increased Functional Connectivity between Prefrontal Cortex and Reward System in Pathological Gambling. ( 26196675 )
2015
48
Parental bonding in subjects with pathological gambling disorder compared with healthy controls. ( 25447192 )
2015
49
The "Pathological Gambling and Epidemiology" (PAGE) study program: design and fieldwork. ( 25583586 )
2015
50
Piribedil and pathological gambling in six parkinsonian patients. ( 25742580 )
2015

Variations for Pathological Gambling

Expression for Pathological Gambling

Search GEO for disease gene expression data for Pathological Gambling.

Pathways for Pathological Gambling

Pathways related to Pathological Gambling according to GeneCards Suite gene sharing:

(show all 22)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.56 DRD1 DRD2 DRD3 DRD4
2
Show member pathways
12.17 DRD1 DRD2 HTR2A
3 12.13 DRD1 DRD2 DRD3 DRD4
4
Show member pathways
11.98 DRD1 DRD2 DRD4
6 11.96 HTR2A MAOA SLC6A4
7
Show member pathways
11.83 DRD1 DRD2 DRD3 DRD4 MAOA MAOB
8 11.69 DRD3 DRD4 HTR2A
9
Show member pathways
11.68 DRD2 DRD3 DRD4
10 11.68 HTR2A MAOA MAOB SLC6A4
11
Show member pathways
11.62 DRD1 DRD2 MAOA MAOB SLC6A3
12
Show member pathways
11.41 DRD1 DRD2 DRD3 DRD4 HTR2A
13
Show member pathways
11.32 MAOA MAOB
14
Show member pathways
11.27 MAOA SLC6A3 SLC6A4
15
Show member pathways
11.14 MAOA MAOB
16 11.09 MAOB SLC6A3
17 11.06 HTR2A MAOA SLC6A4
18
Show member pathways
11.01 MAOA SLC6A3 SLC6A4
19 10.94 DRD1 DRD2 DRD3
20 10.69 MAOA MAOB
21
Show member pathways
10.68 MAOA MAOB
22
Show member pathways
10.64 MAOA MAOB

GO Terms for Pathological Gambling

Cellular components related to Pathological Gambling according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 9.91 DRD1 DRD2 DRD3 DRD4 HTR2A MAOA
2 integral component of membrane GO:0016021 9.61 DRD1 DRD2 DRD3 DRD4 HTR2A MAOA
3 axon GO:0030424 9.5 DRD2 HTR2A SLC6A3
4 integral component of plasma membrane GO:0005887 9.17 DRD1 DRD2 DRD3 DRD4 HTR2A SLC6A3
5 non-motile cilium GO:0097730 9.16 DRD1 DRD2

Biological processes related to Pathological Gambling according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
id Name GO ID Score Top Affiliating Genes
1 response to ethanol GO:0045471 9.88 DRD2 DRD3 MAOB SLC6A3
2 response to toxic substance GO:0009636 9.85 DRD2 MAOB SLC6A4
3 cellular calcium ion homeostasis GO:0006874 9.84 DRD3 DRD4 HTR2A
4 locomotory behavior GO:0007626 9.83 DRD1 DRD2 DRD3 SLC6A3
5 memory GO:0007613 9.81 DRD1 HTR2A SLC6A4
6 social behavior GO:0035176 9.8 DRD3 DRD4 SLC6A4
7 visual learning GO:0008542 9.8 DRD1 DRD2 DRD3
8 negative regulation of adenylate cyclase activity GO:0007194 9.77 DRD2 DRD3 DRD4
9 arachidonic acid secretion GO:0050482 9.76 DRD2 DRD3 DRD4
10 response to cocaine GO:0042220 9.76 DRD1 DRD2 DRD3 SLC6A3
11 regulation of dopamine secretion GO:0014059 9.74 DRD2 DRD3 HTR2A
12 negative regulation of protein kinase B signaling GO:0051898 9.73 DRD2 DRD3
13 neurotransmitter transport GO:0006836 9.73 SLC6A3 SLC6A4
14 feeding behavior GO:0007631 9.73 DRD1 DRD2
15 response to nicotine GO:0035094 9.73 DRD2 SLC6A3
16 release of sequestered calcium ion into cytosol GO:0051209 9.73 DRD2 HTR2A
17 temperature homeostasis GO:0001659 9.73 DRD1 DRD2 HTR2A
18 positive regulation of cytokinesis GO:0032467 9.72 DRD2 DRD3
19 positive regulation of multicellular organism growth GO:0040018 9.72 DRD2 SLC6A3
20 negative regulation of blood pressure GO:0045776 9.72 DRD2 DRD3
21 response to morphine GO:0043278 9.72 DRD2 DRD3
22 adult walking behavior GO:0007628 9.72 DRD1 DRD2
23 synaptic transmission, dopaminergic GO:0001963 9.72 DRD1 DRD2 DRD3
24 behavioral fear response GO:0001662 9.71 DRD1 DRD4
25 associative learning GO:0008306 9.71 DRD1 DRD2
26 response to iron ion GO:0010039 9.71 DRD2 SLC6A3
27 behavioral response to ethanol GO:0048149 9.71 DRD2 DRD4
28 negative regulation of protein secretion GO:0050709 9.71 DRD2 DRD3 DRD4
29 response to amphetamine GO:0001975 9.71 DRD1 DRD2 DRD3 DRD4
30 positive regulation of kinase activity GO:0033674 9.7 DRD4 HTR2A
31 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.7 DRD2 HTR2A
32 neurotransmitter biosynthetic process GO:0042136 9.7 SLC6A3 SLC6A4
33 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.7 DRD1 DRD2
34 negative regulation of voltage-gated calcium channel activity GO:1901386 9.69 DRD2 DRD4
35 grooming behavior GO:0007625 9.69 DRD1 DRD2
36 ammonium transmembrane transport GO:0072488 9.69 SLC6A3 SLC6A4
37 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.69 DRD2 DRD3 DRD4
38 positive regulation of renal sodium excretion GO:0035815 9.68 DRD2 DRD3
39 G-protein coupled receptor internalization GO:0002031 9.68 DRD2 DRD3
40 striatum development GO:0021756 9.68 DRD1 DRD2
41 neurotransmitter catabolic process GO:0042135 9.67 MAOA MAOB
42 peristalsis GO:0030432 9.67 DRD1 DRD2
43 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.67 DRD1 DRD3
44 regulation of dopamine metabolic process GO:0042053 9.67 DRD1 DRD4 SLC6A3
45 adenohypophysis development GO:0021984 9.66 DRD2 SLC6A3
46 monoamine transport GO:0015844 9.65 SLC6A3 SLC6A4
47 dopamine transport GO:0015872 9.65 DRD1 SLC6A3
48 dopamine uptake involved in synaptic transmission GO:0051583 9.65 SLC6A3 SLC6A4
49 dopamine catabolic process GO:0042420 9.65 MAOA MAOB SLC6A3
50 regulation of cAMP metabolic process GO:0030814 9.64 DRD2 DRD3

Molecular functions related to Pathological Gambling according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor activity GO:0004930 9.85 DRD1 DRD2 DRD3 DRD4 HTR2A
2 signal transducer activity GO:0004871 9.72 DRD1 DRD2 DRD3 DRD4 HTR2A
3 drug binding GO:0008144 9.55 DRD2 DRD3 DRD4 HTR2A SLC6A3
4 neurotransmitter:sodium symporter activity GO:0005328 9.48 SLC6A3 SLC6A4
5 monoamine transmembrane transporter activity GO:0008504 9.43 SLC6A3 SLC6A4
6 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.43 DRD2 DRD3 DRD4
7 primary amine oxidase activity GO:0008131 9.4 MAOA MAOB
8 dopamine:sodium symporter activity GO:0005330 9.37 SLC6A3 SLC6A4
9 dopamine neurotransmitter receptor activity GO:0004952 9.26 DRD1 DRD2 DRD3 DRD4
10 dopamine binding GO:0035240 9.02 DRD1 DRD2 DRD3 DRD4 SLC6A3

Sources for Pathological Gambling

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....